FDA approves next generation of Abbott’s MitraClip heart valve device

Abbott’s third-generation MitraClip transcatheter heart valve repair device got an FDA nod. (Abbott)

The FDA approved Abbott’s third-generation MitraClip transcatheter heart valve repair device that boasts advanced steering, navigation and positioning for placement by cardiologists.

The device, which was first approved by the U.S. regulatory agency in 2013, has been used to treat more than 65,000 patients globally in the past decade, the company said. That latest version, which won a CE Mark earlier this year, was designed for more precise placement during noninvasive surgery that allows for more predictable procedures, the company said.

The MitraClip is used to treat patients with significant degenerative mitral regurgitation and is delivered by a catheter inserted through the femoral vein in the leg. It then clips together parts of the mitral valve in a procedure that is less invasive than regular surgery.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Physicians rely on MitraClip as an alternative to surgery for patients who aren’t surgical candidates and may need treatment to relieve their symptoms or to survive,” Francesco Maisano, M.D., of the UniversitätsSpital Zürich, and an early user of the device, said in a statement. “The enhanced MitraClip design allows for even more precise navigation, accuracy and stability during valve repairs, which may be important when treating people with more complex or advanced valve disease.”

Additionally, the company announced it has begun enrollment in the MitraClip EXPAND clinical study that will evaluate the safety and performance of the new MitraClip system in a contemporary real-world setting. About 1,000 patients in 50 sites located in the U.S. and Europe are expected to be part of the study.

Suggested Articles

The FDA warned healthcare providers about cybersecurity vulnerabilities within certain clinical information systems made by GE Healthcare.

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

As public fascination with at-home DNA tests begins to wane, 23andMe announced that it will lay off about 100 of its staff, according to CNBC.